Gabriela Henrykowska

Department of Epidemiology and Public Health, Medical University of Lodz, Żeligowskiego 7/9, 90-752 Lodz, Poland.

2 papers in the library · 21 citations · publishing 2025

Papers

Unveiling the Anti-Inflammatory Effects of Antidepressants: A Systematic Review of Human Studies over the Last Decade.

Pharmaceuticals (Basel, Switzerland) June 10, 2025 Layla Bleibel, Paulina Sokołowska, Gabriela Henrykowska et al. 18 citations

Antidepressants like SSRIs, SNRIs, esketamine, and ketamine reduce inflammation in people with depression by lowering pro-inflammatory cytokines or boosting anti-inflammatory cytokines in the blood and brain regions such as the hippocampus and prefrontal cortex. These effects occur through multiple pathways, including NF-κB, the NLRP3 inflammasome, the glutamatergic system, the gut-brain axis, the hypothalamic-pituitary axis, impaired neuroplasticity, and the kynurenine pathway. The findings suggest that anti-inflammatory actions contribute to the therapeutic benefits of these treatments, supporting the link between depression and inflammation.

DOI: 10.3390/ph18060867 Full text Ketamine Snri Ssri Depression-inflammation link +2

Molecular Mechanisms of Emerging Antidepressant Strategies: From Ketamine to Neuromodulation

International Journal of Molecular Sciences December 28, 2025 Mateusz Kowalczyk, David Aebisher, Jakub Szpara et al. 3 citations

Depression is a common and potentially life-threatening disorder affecting over 300 million people worldwide, with major depressive disorder increasing suicide risk. Its causes involve genetic vulnerability, chronic stress, HPA axis dysregulation, neuroinflammation, oxidative stress, mitochondrial dysfunction, and impaired synaptic plasticity. This review synthesizes data on pharmacological treatments—including SSRIs, SNRIs, TCAs, and MAOIs—and emerging therapies targeting glutamatergic, GABAergic, and dopaminergic systems, such as ketamine, esketamine, dextromethorphan-bupropion, neurosteroids, and selective receptor modulators. It also covers non-pharmacological neuromodulation like TMS, tDCS, and photobiomodulation, integrating molecular mechanisms with depression pathophysiology to inform precise, multimodal treatment strategies.

DOI: 10.3390/ijms27010344 Major depressive disorder Treatment-resistant depression Neuromodulation Monoaminergic +13